Kodiak Sciences

Kodiak Sciences

We are a clinical stage biopharma company bringing new science to prevent and treat high prevalence retinal diseases.

Founded 2009

Palo Alto, United States 108 employees Post-IPO Equity Biotechnology, Health Care +1

Kodiak Sciences is a clinical stage biopharma company dedicated to the research, development, and commercialization of transformative therapeutics for high prevalence retinal diseases. The company's ABC Platform™ integrates antibody-based and chemistry-based therapies, serving as the foundation for Kodiak's discovery engine. Their lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate designed to address retinal vascular diseases, including wet age-related macular degeneration and diabetic eye diseases. Kodiak has leveraged its ABC Platform to construct a pipeline of product candidates, including KSI-501, a dual inhibitor antibody biopolymer conjugate targeting VEGF and IL-6 for the treatment of retinal diseases. The company is also expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Founded in 2009, Kodiak Sciences operates in the biotechnology, health care, and health and wellness sectors, with its headquarters situated in the United States. The company's culture is marked by curiosity, creativity, compassion, and courage, with a collective goal to make a difference in the world. Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance for its employees. The company is located in Palo Alto, at the heart of the world-class biotech hub of Silicon Valley, within walking distance to California Avenue’s shops, restaurants, and public transportation. As of now, there is no publicly available information regarding the company's last investment or the associated investors.

FAQ About Kodiak Sciences

We are a clinical stage biopharma company bringing new science to prevent and treat high prevalence retinal diseases.

Kodiak Sciences was founded in 2009.

Kodiak Sciences is headquartered in Palo Alto, United States.

Kodiak Sciences operates in Biotechnology, Health Care and Health and Wellness.

Kodiak Sciences has approximately 108 employees.

Top alternatives and competitors to Kodiak Sciences include Atsena Therapeutics, Kinarus Therapeutics, Lineage Cell Therapeutics, Onena Medicines, BreStem Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Kodiak Sciences and Atsena Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Kodiak Sciences

Kodiak Sciences Alternatives & Competitors

FAQ About Kodiak Sciences